Recombinant Human Erythropoietin (rhEPO) - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509247853

Publication Date:

September 23, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The process of supplying EPO externally, usually with the help of recombinant DNA technology in a cell culture, is known as rhEPO. rhEPO is used to treat anemia due to neural diseases, injuries, kidney diseases or cancer.
The global market for Recombinant Human Erythropoietin (rhEPO) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Human Erythropoietin (rhEPO) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Human Erythropoietin (rhEPO) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Recombinant Human Erythropoietin (rhEPO) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Recombinant Human Erythropoietin (rhEPO) include 3SBio, Shanghai Chemo, Chengdu Diao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus and Dragon Pharma, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Erythropoietin (rhEPO), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Human Erythropoietin (rhEPO) by region & country, by Type, and by Application.
The Recombinant Human Erythropoietin (rhEPO) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Erythropoietin (rhEPO).
麻豆原创 Segmentation
By Company
3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma
Segment by Type:
ESRD
Cancer
HIV
Wounds and Neural Disease
Segment by Application
Hospitals
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Human Erythropoietin (rhEPO) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant Human Erythropoietin (rhEPO) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant Human Erythropoietin (rhEPO) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Recombinant Human Erythropoietin (rhEPO) Product Introduction
1.2 Global Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Size Forecast
1.2.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Value (2019-2030)
1.2.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume (2019-2030)
1.2.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Price (2019-2030)
1.3 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Trends & Drivers
1.3.1 Recombinant Human Erythropoietin (rhEPO) Industry Trends
1.3.2 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Drivers & Opportunity
1.3.3 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Challenges
1.3.4 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Human Erythropoietin (rhEPO) Players Revenue Ranking (2023)
2.2 Global Recombinant Human Erythropoietin (rhEPO) Revenue by Company (2019-2024)
2.3 Global Recombinant Human Erythropoietin (rhEPO) Players Sales Volume Ranking (2023)
2.4 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Company Players (2019-2024)
2.5 Global Recombinant Human Erythropoietin (rhEPO) Average Price by Company (2019-2024)
2.6 Key Manufacturers Recombinant Human Erythropoietin (rhEPO) Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Recombinant Human Erythropoietin (rhEPO) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Human Erythropoietin (rhEPO)
2.9 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Competitive Analysis
2.9.1 Recombinant Human Erythropoietin (rhEPO) 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Human Erythropoietin (rhEPO) Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Erythropoietin (rhEPO) as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ESRD
3.1.2 Cancer
3.1.3 HIV
3.1.4 Wounds and Neural Disease
3.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Type
3.2.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Value, by Type (%) (2019-2030)
3.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Type
3.3.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume, by Type (2019-2030)
3.3.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume, by Type (%) (2019-2030)
3.4 Global Recombinant Human Erythropoietin (rhEPO) Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Retail Pharmacies
4.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Application
4.2.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Value, by Application (%) (2019-2030)
4.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Application
4.3.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume, by Application (2019-2030)
4.3.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume, by Application (%) (2019-2030)
4.4 Global Recombinant Human Erythropoietin (rhEPO) Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Region
5.1.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Human Erythropoietin (rhEPO) Sales Value by Region (%), (2019-2030)
5.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Region
5.2.1 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Region (2019-2024)
5.2.3 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Region (2025-2030)
5.2.4 Global Recombinant Human Erythropoietin (rhEPO) Sales Volume by Region (%), (2019-2030)
5.3 Global Recombinant Human Erythropoietin (rhEPO) Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
5.4.2 North America Recombinant Human Erythropoietin (rhEPO) Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
5.5.2 Europe Recombinant Human Erythropoietin (rhEPO) Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
5.6.2 Asia Pacific Recombinant Human Erythropoietin (rhEPO) Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
5.7.2 South America Recombinant Human Erythropoietin (rhEPO) Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
5.8.2 Middle East & Africa Recombinant Human Erythropoietin (rhEPO) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Human Erythropoietin (rhEPO) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Human Erythropoietin (rhEPO) Sales Value
6.2.1 Key Countries/Regions Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.2.2 Key Countries/Regions Recombinant Human Erythropoietin (rhEPO) Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.3.2 United States Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.4.2 Europe Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.5.2 China Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.6.2 Japan Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.7.2 South Korea Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Human Erythropoietin (rhEPO) Sales Value, 2019-2030
6.9.2 India Recombinant Human Erythropoietin (rhEPO) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Human Erythropoietin (rhEPO) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 3SBio
7.1.1 3SBio Company Information
7.1.2 3SBio Introduction and Business Overview
7.1.3 3SBio Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.1.4 3SBio Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.1.5 3SBio Recent Development
7.2 Shanghai Chemo
7.2.1 Shanghai Chemo Company Information
7.2.2 Shanghai Chemo Introduction and Business Overview
7.2.3 Shanghai Chemo Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Shanghai Chemo Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.2.5 Shanghai Chemo Recent Development
7.3 Chengdu Diao
7.3.1 Chengdu Diao Company Information
7.3.2 Chengdu Diao Introduction and Business Overview
7.3.3 Chengdu Diao Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Chengdu Diao Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.3.5 Chengdu Diao Recent Development
7.4 NCPC Genetech
7.4.1 NCPC Genetech Company Information
7.4.2 NCPC Genetech Introduction and Business Overview
7.4.3 NCPC Genetech Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.4.4 NCPC Genetech Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.4.5 NCPC Genetech Recent Development
7.5 Kyowa Hakko Kirin
7.5.1 Kyowa Hakko Kirin Company Information
7.5.2 Kyowa Hakko Kirin Introduction and Business Overview
7.5.3 Kyowa Hakko Kirin Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Kyowa Hakko Kirin Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.5.5 Kyowa Hakko Kirin Recent Development
7.6 Shandong Kexing
7.6.1 Shandong Kexing Company Information
7.6.2 Shandong Kexing Introduction and Business Overview
7.6.3 Shandong Kexing Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Shandong Kexing Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.6.5 Shandong Kexing Recent Development
7.7 Ahua Pharmaceutical
7.7.1 Ahua Pharmaceutical Company Information
7.7.2 Ahua Pharmaceutical Introduction and Business Overview
7.7.3 Ahua Pharmaceutical Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Ahua Pharmaceutical Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.7.5 Ahua Pharmaceutical Recent Development
7.8 Biosidus
7.8.1 Biosidus Company Information
7.8.2 Biosidus Introduction and Business Overview
7.8.3 Biosidus Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Biosidus Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.8.5 Biosidus Recent Development
7.9 Dragon Pharma
7.9.1 Dragon Pharma Company Information
7.9.2 Dragon Pharma Introduction and Business Overview
7.9.3 Dragon Pharma Recombinant Human Erythropoietin (rhEPO) Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Dragon Pharma Recombinant Human Erythropoietin (rhEPO) Product Offerings
7.9.5 Dragon Pharma Recent Development
8 Industry Chain Analysis
8.1 Recombinant Human Erythropoietin (rhEPO) Industrial Chain
8.2 Recombinant Human Erythropoietin (rhEPO) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Human Erythropoietin (rhEPO) Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Human Erythropoietin (rhEPO) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.